loading
Galectin Therapeutics Inc stock is traded at $2.8399, with a volume of 18,652. It is up +0.18% in the last 24 hours and up +7.22% over the past month.
See More
Previous Close:
$2.815
Open:
$2.85
24h Volume:
18,652
Relative Volume:
0.14
Market Cap:
$138.59M
Revenue:
-
Net Income/Loss:
$-41.07M
P/E Ratio:
-4.3029
EPS:
-0.66
Net Cash Flow:
$-32.97M
1W Performance:
+2.55%
1M Performance:
+7.22%
6M Performance:
-12.69%
1Y Performance:
+44.62%
1-Day Range:
Value
$2.76
$2.85
1-Week Range:
Value
$2.646
$2.88
52-Week Range:
Value
$1.555
$4.2684

Galectin Therapeutics Inc Stock (GALT) Company Profile

Name
Name
Galectin Therapeutics Inc
Name
Phone
678-620-3186
Name
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Name
Employee
0
Name
Twitter
@galectingalt
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
GALT's Discussions on Twitter

Compare GALT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
GALT 2.835 138.59M 0 -41.07M -32.97M -0.66
VRTX 447.00 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.05 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 586.52 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.92 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.72 24.49B 3.30B -501.07M 1.03B 11.54

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-13-20 Reiterated H.C. Wainwright Buy
Feb-13-19 Initiated B. Riley FBR Buy
Dec-07-17 Reiterated H.C. Wainwright Buy
Nov-28-17 Reiterated H.C. Wainwright Buy
Oct-19-17 Initiated ROTH Capital Buy
Mar-30-17 Upgrade H.C. Wainwright Neutral → Buy
Oct-03-16 Downgrade FBR & Co. Outperform → Mkt Perform
Sep-29-16 Downgrade H.C. Wainwright Buy → Neutral
Sep-28-16 Downgrade ROTH Capital Buy → Sell
Mar-28-16 Resumed H.C. Wainwright Buy
Sep-21-15 Initiated H.C. Wainwright Buy
Aug-01-14 Downgrade Aegis Capital Buy → Hold
Jul-30-14 Reiterated MLV & Co Buy
Jul-29-14 Reiterated MLV & Co Buy
Apr-02-14 Reiterated MLV & Co Buy
Feb-10-14 Reiterated Aegis Capital Buy
Jan-09-14 Reiterated Aegis Capital Buy
Dec-03-13 Initiated MLV & Co Buy
Aug-19-13 Reiterated Aegis Capital Buy
View All

Galectin Therapeutics Inc Stock (GALT) Latest News

pulisher
Nov 20, 2024

StockNews.com Upgrades Galectin Therapeutics (NASDAQ:GALT) to "Hold" - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com - Defense World

Nov 20, 2024
pulisher
Nov 19, 2024

Non-alcoholic Steatohepatitis Treatment Market Projected to Show Strong Growth - openPR

Nov 19, 2024
pulisher
Nov 18, 2024

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Galectin Therapeutics Advances NAVIGATE Trial for MASH Cirrhosis Treatment, December Readout on Track | GALT Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

HC Wainwright Analysts Decrease Earnings Estimates for GALT - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Galectin Therapeutics (NASDAQ:GALT) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Galectin Therapeutics Reports Increased Q3 Losses - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Galectin Therapeutics Inc (GALT) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 14, 2024

Galectin Therapeutics Advances Galectin-Based Therapeutics Pipeline - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21 - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Galectin Q3 Loss Narrows to $11.2M; Key NAVIGATE Trial Results Due December | GALT Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 13, 2024

Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight - The Malaysian Reserve

Nov 13, 2024
pulisher
Nov 07, 2024

Galectin Therapeutics (NASDAQ: GALT): Disrupting Merck’s Cancer Dominance - Insider Financial

Nov 07, 2024
pulisher
Nov 07, 2024

Individual investors who hold 54% of Galectin Therapeutics Inc. (NASDAQ:GALT) gained 12%, insiders profited as well - Simply Wall St

Nov 07, 2024
pulisher
Nov 05, 2024

Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart

Nov 05, 2024
pulisher
Nov 05, 2024

Non-Alcoholic Steatohepatitis Market to Show Remarkable - openPR

Nov 05, 2024
pulisher
Oct 29, 2024

Psoriasis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart

Oct 29, 2024
pulisher
Oct 29, 2024

Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Recent Developments | Astrazeneca, Bayer, Sanofi, Pfizer, Merck, Novartis - Barchart

Oct 29, 2024
pulisher
Oct 29, 2024

Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, - openPR

Oct 29, 2024
pulisher
Oct 28, 2024

LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR

Oct 28, 2024
pulisher
Oct 23, 2024

Galectin therapeutics director Eldred Kary buys $1,300 in stock By Investing.com - Investing.com South Africa

Oct 23, 2024
pulisher
Oct 23, 2024

Galectin therapeutics director Eldred Kary buys $1,300 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 17, 2024

Galectin therapeutics director Freeman buys $27,000 in stock By Investing.com - Investing.com Canada

Oct 17, 2024
pulisher
Oct 16, 2024

Galectin therapeutics director Freeman buys $27,000 in stock - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $13,500.00 in Stock - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at StockNews.com - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

Application Monitoring Suites Market Size and Industry Overview - News in Assen

Oct 15, 2024
pulisher
Oct 15, 2024

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: - openPR

Oct 15, 2024
pulisher
Oct 15, 2024

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail

Oct 15, 2024
pulisher
Oct 15, 2024

Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail

Oct 15, 2024
pulisher
Oct 15, 2024

Nonalcoholic Steatohepatitis Treatment Market Size, Innovations Driving Market Evolution (2024-2034) - IndiaPolitics.com

Oct 15, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

AXT, Inc. (NASDAQ:AXTI) Stock Holdings Trimmed by Marshall Wace LLP - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

The Manufacturers Life Insurance Company Has $951,000 Stock Holdings in Huntsman Co. (NYSE:HUN) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Buys New Holdings in Hanesbrands Inc. (NYSE:HBI) - Defense World

Oct 14, 2024
pulisher
Oct 06, 2024

Research Analysts’ Updated EPS Estimates for October 6th (APVO, CNP, FDX, FLNT, FRD, GALT, HOPE, KBR, LSXMK, NVGS) - Defense World

Oct 06, 2024
pulisher
Oct 06, 2024

Galectin Therapeutics (NASDAQ:GALT) Rating Increased to Hold at StockNews.com - Defense World

Oct 06, 2024
pulisher
Oct 06, 2024

Galectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.com - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Global Non-Alcoholic Steatohepatitis Treatment Market Overview And Statistics For 2024-2033 - EIN News

Oct 04, 2024
pulisher
Oct 02, 2024

Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight - The Malaysian Reserve

Oct 02, 2024
pulisher
Oct 02, 2024

Rhumbline Advisers Purchases New Holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Oct 02, 2024
pulisher
Sep 30, 2024

Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference - The Manila Times

Sep 30, 2024
pulisher
Sep 30, 2024

Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - The Manila Times

Sep 30, 2024
pulisher
Sep 29, 2024

Galectin Therapeutics (FRA:PHPN) Interest Expense : €-3.71 Mil (TTM As of Jun. 2024) - GuruFocus.com

Sep 29, 2024
pulisher
Sep 29, 2024

Galectin Therapeutics (FRA:PHPN) Change In Prepaid Assets : €-0.16 Mil (TTM As of Jun. 2024) - GuruFocus.com

Sep 29, 2024
pulisher
Sep 28, 2024

StockNews.com Lowers Galectin Therapeutics (NASDAQ:GALT) to Sell - MarketBeat

Sep 28, 2024

Galectin Therapeutics Inc Stock (GALT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):